Published • loading... • Updated
Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High - What's Next?
Lundbeck is working with advisers as Xeris reported $91 million in second-quarter revenue on strong demand for Recorlev, Bloomberg said.
Summary by MarketBeat
5 Articles
5 Articles
Lundbeck expresses interest in buying Xeris, Bloomberg News reports - Regional Media News
Sept 29 (Reuters) - Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma, Bloomberg News reported on Tuesday, citing people familiar with the matter. Lundbeck has been working with advisers to explore a takeover of Xeris, according to the report. Lundbeck [...]
Lundbeck expresses interest in buying Xeris, Bloomberg News reports
Sept 29 (Reuters) - Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma, Bloomberg News reported on Tuesday, citing people familiar with the matter. Lundbeck has been working with advisers to explore a ta...
Coverage Details
Total News Sources5
Leaning Left0Leaning Right2Center2Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
